{"id":"rhil-11","_chembl":{"chemblId":"CHEMBL2109509","moleculeType":"Unknown"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=rhIL-11","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:56:34.123301+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:56:38.982848+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rhIL-11","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:56:39.314067+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tumor necrosis factor receptor superfamily member 3 agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:56:41.402017+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109509/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:56:41.062724+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-28T00:04:59.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:56:42.718311+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07362810","phase":"PHASE2","title":"G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-01","conditions":"Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation, Hemato-oncologic Patients","enrollment":224},{"nctId":"NCT07185893","phase":"NA","title":"A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Jun wang","startDate":"2025-09","conditions":"Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia, Thrombocytopenia","enrollment":106},{"nctId":"NCT06759636","phase":"PHASE3","title":"FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-01-21","conditions":"CTIT: Cancer Therapy Induced Thrombocytopenia","enrollment":88},{"nctId":"NCT05909293","phase":"NA","title":"Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-04-12","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT05688306","phase":"","title":"To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment","status":"COMPLETED","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2020-09-02","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":3494},{"nctId":"NCT04915287","phase":"PHASE4","title":"Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-06-06","conditions":"Thrombocytopenia; Drugs, Chronic Liver Disease","enrollment":476},{"nctId":"NCT04597073","phase":"NA","title":"Measurement of Oncostatin M, Leukemia Inhibitory Factor and Interleukin-11 Levels of Patients With Periodontal Disease","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2014-03","conditions":"Chronic Periodontitis, Generalized, Gingivitis","enrollment":72},{"nctId":"NCT01663441","phase":"PHASE3","title":"A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11","status":"COMPLETED","sponsor":"Beijing Northland Biotech. Co., Ltd.","startDate":"2015-03","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":62},{"nctId":"NCT03720340","phase":"PHASE3","title":"Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2018-10-01","conditions":"Nasopharyngeal Carcinoma","enrollment":300},{"nctId":"NCT00524225","phase":"PHASE2","title":"IL-11 in Adults With Von Willebrand Disease Undergoing Surgery","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2008-02","conditions":"Von Willebrand Disease","enrollment":3},{"nctId":"NCT03823079","phase":"PHASE2","title":"Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-02-01","conditions":"Recurrent Colorectal Carcinoma, Thrombopenia","enrollment":50},{"nctId":"NCT00012298","phase":"PHASE1, PHASE2","title":"Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-04","conditions":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":81},{"nctId":"NCT00524342","phase":"PHASE2","title":"IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia","status":"COMPLETED","sponsor":"Margaret Ragni","startDate":"2008-01","conditions":"Von Willebrand Disease","enrollment":7},{"nctId":"NCT00886743","phase":"PHASE2","title":"Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-09","conditions":"Severe Thrombocytopenia","enrollment":19},{"nctId":"NCT03049774","phase":"","title":"A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor","status":"UNKNOWN","sponsor":"Angde Biotech Pharmaceutical Co., Ltd.","startDate":"2017-02-28","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":2000},{"nctId":"NCT00151125","phase":"PHASE2","title":"Phase II Study of IL-11 (Neumega) in Von Willebrand Disease","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2004-07","conditions":"Von Willebrand Disease","enrollment":12},{"nctId":"NCT01317966","phase":"","title":"Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia","status":"WITHDRAWN","sponsor":"Ming Hou","startDate":"2011-03","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":""},{"nctId":"NCT00994929","phase":"PHASE2","title":"Efficacy and Safety of IL-11 in DDAVP Unresponsive","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2010-01","conditions":"Hemophilia A, Von Willebrand Disease","enrollment":9},{"nctId":"NCT02281240","phase":"","title":"Hemostatic Complications in Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2014-12","conditions":"Hemostatic Disorders","enrollment":200},{"nctId":"NCT02344979","phase":"","title":"The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC","status":"UNKNOWN","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2009-05","conditions":"Thrombocytopenia","enrollment":120},{"nctId":"NCT02314273","phase":"PHASE4","title":"Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL","status":"COMPLETED","sponsor":"Shanghai Children's Medical Center","startDate":"2011-09","conditions":"Pancytopenia Due to Chemotherapy","enrollment":120},{"nctId":"NCT02241031","phase":"PHASE2, PHASE3","title":"Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2014-09","conditions":"Hematological Diseases, Thrombocytopenia","enrollment":250},{"nctId":"NCT00040521","phase":"PHASE2","title":"Study Evaluating rhIL-11 in Active Crohn's Disease","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-04","conditions":"Crohn Disease, Inflammatory Bowel Disease","enrollment":""},{"nctId":"NCT00493181","phase":"PHASE2","title":"Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-10","conditions":"Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia","enrollment":8},{"nctId":"NCT00004157","phase":"PHASE2","title":"Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2000-08","conditions":"Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer","enrollment":""},{"nctId":"NCT00038922","phase":"PHASE1","title":"Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Ulcerative Colitis, Inflammatory Bowel Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"OEDEMA PERIPHERAL"},{"count":2,"reaction":"DRUG TOXICITY"},{"count":1,"reaction":"ANALGESIA"},{"count":1,"reaction":"ARTHRITIS"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"BLOOD UREA INCREASED"},{"count":1,"reaction":"CIRCULATORY COLLAPSE"},{"count":1,"reaction":"DEPRESSED LEVEL OF CONSCIOUSNESS"},{"count":1,"reaction":"DRUG INTERACTION"}],"crossReferences":{"chemblId":"CHEMBL2109509"},"_approvalHistory":[],"publicationCount":229,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant Human Interleukin-11","Recombinant Human Interleukin-11 for Injection","Rituximab","ITP"],"phase":"marketed","status":"active","brandName":"rhIL-11","genericName":"rhIL-11","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:56:42.718311+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}